Shares of Edesa Biotech tumbled 10% to $4.28 after the Toronto-based clinical-stage drugmaker priced a $25 million underwritten public offering — a deal that hands the company a longer financial runway but floods the market with new stock at a steep discount to where shares had been trading.
The Deal Slashes the Entry Price and Adds Millions of New Shares. The offering consists of 3,870,500 common shares and up to 675,000 pre-funded warrants, each bundled with an accompanying warrant to buy one additional share , priced at $5.50 per unit, with the accompanying warrants carrying a $7.50 strike price and immediately exercisable from issuance. That $5.50 price represented a roughly 4% discount to the prior close of $5.75 — but the real dilution math is worse. Edesa had roughly 9.6 million shares outstanding as of mid-June 2026. If all new shares and warrants convert, the share count could swell by roughly 9.1 million — nearly doubling the float. Existing shareholders' slice of the pie gets cut almost in half.
The Company Was Running Out of Cash. Edesa reported just $10.3 million in cash as of June 30, 2026, alongside a quarterly net loss of $5.4 million — meaning, at that burn rate, the company had less than two quarters of runway. The raise was not optional; it was existential. Edesa had already raised $3.5 million via a CEO-led private placement completed in June 2026 , but that was plainly insufficient.
The Money Funds a High-Stakes Vitiligo Trial. The primary asset supported by this financing is an antibody drug candidate in a Phase II study for moderate-to-severe vitiligo , a skin condition with limited approved treatments. The company began activating its first trial sites and expects patient recruitment to begin in the coming weeks in Canada.
Notably, the warrants expire just 30 days after Edesa publicly announces Phase II results — a structure that ties investors' upside directly to trial success and pressures a near-term readout.
The Stock Has Cratered from Recent Highs, Raising the Stakes. Shares traded near $12 in May, meaning today's $4.28 price reflects a roughly 64% collapse in three months. Guggenheim Securities is the sole book-runner , and Edesa plans to direct proceeds toward working capital, R&D, and manufacturing. For shareholders, the calculus is brutally simple: the company bought time to reach a clinical inflection point, but at the cost of massive dilution. A positive Phase II readout could justify the bet; a failure would leave investors holding far more shares worth far less.